QNRX ▲ +57.0% - Quoin Pharmaceuticals, Ltd. $QNRX - Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome Quoin Pharmaceuticals' stock surged 57% today following the company's announcement of positive interim data from its Phase 2/3 study of QRX003, a treatment candidate for Netherton Syndrome. The encouraging clinical results likely drove investor optimism about the drug's potential efficacy and the company's prospects for advancing the program toward potential approval. 28-AUG-2026 06:00 AM ET